Last reviewed · How we verify

Randomisation to mepolizumab

Cliniques universitaires Saint-Luc- Université Catholique de Louvain · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Randomisation to mepolizumab is a Small molecule drug developed by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. It is currently FDA-approved. Also known as: Active-controlled.

Mepolizumab is an interleukin-5 inhibitor, classified as an antibody, used to treat conditions such as asthma and severe asthma. It works by inhibiting interleukin-5, a cytokine involved in the growth and activation of eosinophils.

At a glance

Generic nameRandomisation to mepolizumab
Also known asActive-controlled
SponsorCliniques universitaires Saint-Luc- Université Catholique de Louvain
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Randomisation to mepolizumab

What is Randomisation to mepolizumab?

Randomisation to mepolizumab is a Small molecule drug developed by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.

Who makes Randomisation to mepolizumab?

Randomisation to mepolizumab is developed and marketed by Cliniques universitaires Saint-Luc- Université Catholique de Louvain (see full Cliniques universitaires Saint-Luc- Université Catholique de Louvain pipeline at /company/cliniques-universitaires-saint-luc-universit-catholique-de-louvain).

Is Randomisation to mepolizumab also known as anything else?

Randomisation to mepolizumab is also known as Active-controlled.

What development phase is Randomisation to mepolizumab in?

Randomisation to mepolizumab is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing